Welcome to our dedicated page for IGC Pharma news (Ticker: IGC), a resource for investors and traders seeking the latest updates and insights on IGC Pharma stock.
IGC Pharma Inc (NYSE American: IGC) is a clinical-stage biotechnology leader pioneering AI-driven cannabinoid therapies for Alzheimer’s disease, chronic pain, and neurological disorders. This page provides investors and researchers with timely updates on the company’s pharmaceutical advancements, clinical trial progress, and strategic initiatives.
Access comprehensive coverage of IGC’s investigational drug pipeline, including IGC-AD1 for Alzheimer’s-related agitation currently in Phase 2 trials. Stay informed about cutting-edge research integrating artificial intelligence to optimize therapeutic development and diagnostic precision.
Explore updates across key areas: clinical trial milestones, regulatory developments, research partnerships, and product launches from the Holiby™ wellness brand. Our curated news collection ensures you never miss critical updates about IGC’s dual focus on pharmaceutical innovation and consumer health solutions.
Bookmark this page for verified information on IGC Pharma’s advancements in cannabinoid science, AI applications in drug discovery, and market-moving developments. Check regularly for authoritative reporting on one of biotech’s most innovative players.
IGC Pharma (NYSE American:IGC) is expanding its Holiby™ wellness brand with two new product lines: Longevity and Renew, targeting the anti-aging market. The company is implementing a multi-channel commercial strategy through e-commerce, white-label partnerships, and digital marketing.
The new products include Longevity Gummies for cognitive and cellular health support, featuring NAD+ boosting compounds, Lion's Mane Mushroom, and antioxidants, and Renew Gummies for energy and resilience, containing NAD+ metabolism support, Chaga Mushroom, and plant-based adaptogens.
This expansion complements IGC Pharma's clinical-stage drug development, including its Phase 2 trial (CALMA) of IGC-AD1 for Alzheimer's. The company is targeting the global longevity and anti-aging market, projected to exceed $182 billion by 2028, focusing on consumers aged 40+ seeking health-conscious solutions.
IGC Pharma reported its Q3 FY2025 financial results, highlighting progress in its Phase 2 CALMA trial for IGC-AD1, aimed at reducing agitation in Alzheimer's patients. The company generated $257,000 in revenue, a 26% increase from the same period last year, driven by white-label sales of over-the-counter formulations.
Key financial metrics show SG&A expenses decreased by 49% to $1.0 million, while R&D expenses decreased by 6% to $852,000. The net loss was $1.8 million ($0.02 per share), compared to $5.8 million ($0.08 per share) in the previous year. The company plans to expand IGC-AD1's application as an Alzheimer's disease-modifying therapy targeting brain plaques and tangles.
Notable achievements include winning two PREPARE Challenge awards and enrolling patients at Baycrest Academy in Toronto for the CALMA trial. The company also reported positive interim data showing cognitive benefits in Alzheimer's patients.
IGC Pharma has announced the launch of Holiby™, a wellness brand entering the $75 billion wellness market. The company will manufacture immunity and energy gummies at its Washington State facilities, creating a new revenue stream while continuing its pharmaceutical research on Alzheimer's disease and metabolic disorders.
The initial product line includes Immunity Gummies containing Elderberry, Echinacea, and Reishi Mushrooms, and Energy Gummies featuring Ashwagandha, Ginseng, and Maca Root. Products will be sold through direct-to-consumer channels and white-label partnerships.
The company aims to target health-conscious consumers aged 25 to 55+, particularly women (60-70%), through digital marketing, e-commerce, and social media influencer strategies.
IGC Pharma has been selected as one of the top 15 finalists in the PREPARE Challenge - Phase 2: Model Arena (Acoustic Track), organized by the National Institute on Aging (NIA). The company is developing AI-driven tools for early Alzheimer's disease detection using acoustic biomarkers from voice recordings.
The company's approach utilizes multilingual AI models to enhance predictive accuracy across diverse populations, including English, Spanish, and Chinese speakers. This initiative aligns with IGC Pharma's broader mission to integrate AI with pharmaceutical innovation in Alzheimer's care.
The next stage of the competition will focus on demonstrating the AI model's ability to identify cognitive changes across diverse demographic groups. If selected as one of three winners, IGC will work on improving model interpretability while maintaining transparency. With the global Alzheimer's diagnostic market projected to exceed $10 billion by 2028 and over 7 million Americans living with Alzheimer's, early detection remains a critical unmet need.
IGC Pharma (NYSE American:IGC) has appointed Terry McAuliffe, the 72nd Governor of Virginia, as a strategic advisor. McAuliffe will focus on refining growth strategies, driving business development, and fostering partnerships with pharmaceutical and healthcare organizations. His expertise in regulatory landscapes and collaborations is expected to accelerate the company's clinical development efforts.
McAuliffe, who was honored as BIO Governor of the Year in 2016, brings experience across banking, public service, and biosciences. The company's main focus is on IGC-AD1, an investigational therapy targeting agitation in Alzheimer's dementia, with preclinical research suggesting potential disease-modifying properties including reduction of amyloid plaques and tau tangles. IGC Pharma is also developing therapies for metabolic disorders like obesity and diabetes while incorporating AI initiatives for drug discovery.
IGC Pharma (NYSE American: IGC) has announced its participation in a fireside chat hosted by Ascendiant Capital Markets scheduled for January 23, 2025, at 1:00 pm ET. CEO Ram Mukunda and CCO Claudia Grimaldi will lead the discussion.
The management team will provide updates on several key areas including:
- Recent progress in the company's Alzheimer's pipeline
- Strategic expansion into metabolic disorders
- Integration of artificial intelligence in drug discovery
The discussion will also cover upcoming milestones, including:
- New clinical trial launches
- Preclinical developments
- Efforts to expand their addressable market in Alzheimer's disease and weight loss therapies
IGC Pharma has officially named its Phase 2 trial for Alzheimer's agitation as CALMA (Calming Agitation in Alzheimer's). The trial addresses agitation, a condition affecting up to 76% of the 55 million Alzheimer's patients worldwide. The company has implemented an innovative recruitment strategy using geofencing technology and digital outreach through social media platforms.
The pilot recruitment campaign at select trial sites achieved a 200-300% increase in enrollment at a relatively low cost per lead. IGC Pharma is now expanding this strategy across all trial locations in the USA and Canada, targeting individuals within a 15-25-mile radius of clinical sites. The company aims to complete enrollment and the CALMA trial in the second half of 2025.
IGC Pharma announced its participation in BIO Partnering @ JPM, scheduled alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025 from January 13-16, 2025. The company's management team will be available for both in-person and virtual meetings with registered investors and pharmaceutical companies. During these one-on-one meetings, they will present their business strategy, recent partnerships, achievements, and anticipated milestones. IGC will also host separate one-on-one meetings in San Francisco during JPM Week.
IGC Pharma announced an expansion of its clinical research program for IGC-AD1, an investigational Alzheimer's treatment. Building on Phase 2 interim results showing reduced agitation and cognitive improvement, the company plans to initiate new trials in 2025 to evaluate IGC-AD1's potential as a disease-modifying therapy. Preclinical studies demonstrated approximately 50% improvement in spatial memory and 20% reduction in amyloid aggregation. The ongoing 146-patient Phase 2 trial has administered over 1,000 doses with no serious adverse events reported, with comprehensive data expected in 2025.
IGC Pharma has announced additional interim results from its Phase 2 clinical trial of IGC-AD1 for Alzheimer's treatment. The active treatment group showed an average 8% improvement in cognitive function on the Mini-Mental State Examination over six weeks, while the placebo group showed no improvement. The trial primarily focuses on agitation reduction, where IGC-AD1 demonstrated significant improvements compared to placebo within two weeks. These results align with preclinical data showing 20% reduction in amyloid plaque aggregation and 50% improvement in spatial memory in mouse models. No serious adverse events were reported during the trial.
